International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands

Beyond CB1 and CB2

Roger Guy Pertwee, A. C. Howlett, M. E. Abood, S. P. H. Alexander, V. Di Marzo, M. R. Elphick, P. J. Greasley, H. S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, R. A. Ross

Research output: Contribution to journalLiterature review

870 Citations (Scopus)

Abstract

There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid Delta(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endo-cannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB1, non-CB2 established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB1 and/or CB2 receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel "CB3" cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB1, non-CB2 pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB3 receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB1 receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB1/CB2 receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB1, non-CB2 cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

Original languageEnglish
Pages (from-to)588-631
Number of pages44
JournalPharmacological Reviews
Volume62
Issue number4
DOIs
Publication statusPublished - Dec 2010

Keywords

  • protein-coupled-receptor
  • free fatty-acids
  • anandamide-induced vasorelaxation
  • proliferator-activated receptors
  • vanilloid type-1 receptors
  • CA2+-activated K+ channels
  • trigeminal sensory neurons
  • dependent vascular actions
  • potential cation channels
  • N-arachidonoyl-dopamine

Cite this

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands : Beyond CB1 and CB2. / Pertwee, Roger Guy; Howlett, A. C.; Abood, M. E.; Alexander, S. P. H.; Di Marzo, V.; Elphick, M. R.; Greasley, P. J.; Hansen, H. S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R. A.

In: Pharmacological Reviews, Vol. 62, No. 4, 12.2010, p. 588-631.

Research output: Contribution to journalLiterature review

Pertwee, RG, Howlett, AC, Abood, ME, Alexander, SPH, Di Marzo, V, Elphick, MR, Greasley, PJ, Hansen, HS, Kunos, G, Mackie, K, Mechoulam, R & Ross, RA 2010, 'International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2', Pharmacological Reviews, vol. 62, no. 4, pp. 588-631. https://doi.org/10.1124/pr.110.003004
Pertwee, Roger Guy ; Howlett, A. C. ; Abood, M. E. ; Alexander, S. P. H. ; Di Marzo, V. ; Elphick, M. R. ; Greasley, P. J. ; Hansen, H. S. ; Kunos, G. ; Mackie, K. ; Mechoulam, R. ; Ross, R. A. / International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands : Beyond CB1 and CB2. In: Pharmacological Reviews. 2010 ; Vol. 62, No. 4. pp. 588-631.
@article{43516b261b7d43e795076def5e88dd84,
title = "International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2",
abstract = "There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid Delta(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endo-cannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB1, non-CB2 established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB1 and/or CB2 receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel {"}CB3{"} cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB1, non-CB2 pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB3 receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB1 receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB1/CB2 receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB1, non-CB2 cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.",
keywords = "protein-coupled-receptor, free fatty-acids, anandamide-induced vasorelaxation, proliferator-activated receptors, vanilloid type-1 receptors, CA2+-activated K+ channels, trigeminal sensory neurons, dependent vascular actions, potential cation channels, N-arachidonoyl-dopamine",
author = "Pertwee, {Roger Guy} and Howlett, {A. C.} and Abood, {M. E.} and Alexander, {S. P. H.} and {Di Marzo}, V. and Elphick, {M. R.} and Greasley, {P. J.} and Hansen, {H. S.} and G. Kunos and K. Mackie and R. Mechoulam and Ross, {R. A.}",
year = "2010",
month = "12",
doi = "10.1124/pr.110.003004",
language = "English",
volume = "62",
pages = "588--631",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands

T2 - Beyond CB1 and CB2

AU - Pertwee, Roger Guy

AU - Howlett, A. C.

AU - Abood, M. E.

AU - Alexander, S. P. H.

AU - Di Marzo, V.

AU - Elphick, M. R.

AU - Greasley, P. J.

AU - Hansen, H. S.

AU - Kunos, G.

AU - Mackie, K.

AU - Mechoulam, R.

AU - Ross, R. A.

PY - 2010/12

Y1 - 2010/12

N2 - There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid Delta(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endo-cannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB1, non-CB2 established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB1 and/or CB2 receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel "CB3" cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB1, non-CB2 pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB3 receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB1 receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB1/CB2 receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB1, non-CB2 cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

AB - There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid Delta(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endo-cannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB1, non-CB2 established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB1 and/or CB2 receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel "CB3" cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB1, non-CB2 pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB3 receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB1 receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB1/CB2 receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB1, non-CB2 cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

KW - protein-coupled-receptor

KW - free fatty-acids

KW - anandamide-induced vasorelaxation

KW - proliferator-activated receptors

KW - vanilloid type-1 receptors

KW - CA2+-activated K+ channels

KW - trigeminal sensory neurons

KW - dependent vascular actions

KW - potential cation channels

KW - N-arachidonoyl-dopamine

U2 - 10.1124/pr.110.003004

DO - 10.1124/pr.110.003004

M3 - Literature review

VL - 62

SP - 588

EP - 631

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 4

ER -